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Synopsis	
The	aim	of	this	study	is	to	extend	the	AMICO	framework	to	the	VERDICT	model-based	
diffusion-weighted	MRI	(DW-MRI)	technique	and	to	evaluate	its	performance	to	prostate	
cancer	imaging.	DW-MRI	was	acquired	for	4	subjects	and	the	VERDICT	model	was	fitted	to	
the	data	using	both	fitting	procedures.	In	both	cases	similar	differences	in	parameter	values	
between	tumour	and	normal	tissue	were	found.	The	AMICO	formulation	reduces	the	
computation	time	for	VERDICT	and	produces	parameter	maps	that	are	more	homogeneous	
than	those	obtained	with	the	original	fitting.	The	AMICO	formulation	reflects	the	
microstructural	differences	in	a	clinically	practical	time.	
	
Abstract	
Purpose	
The	aim	of	this	study	is	to	extend	the	AMICO1	(Accelerated	Microstructure	Imaging	via	
Convex	Optimisation)	framework	to	the	VERDICT2,3	(Vascular,	Extracellular,	and	Restricted	
Diffusion	for	Cytometry	in	Tumours)	model-based	diffusion-weighted	MRI	(DW-MRI)	
technique	and	to	evaluate	its	performance	in	the	clinical	application	for	prostate	cancer	
imaging.	
Prostate	cancer	is	the	most	common	cancer	among	men	in	all	economically	developed	
countries4.	A	non-invasive	method	of	diagnosis	and	grading	would	revolutionise	clinical	
practice.	VERDICT,	a	model-based	technique,	for	characterising	microstructural	tissue	
parameters	has	shown	promise	in	preclinical	studies2	and	in	a	pilot	clinical	setting3	for	
discriminating	normal	and	malignant	prostate	tissue.	However,	VERDICT	uses	a	
computationally	expensive	non-linear	fitting	procedure	to	estimate	model	parameters	from	
the	data,	which	limits	its	use	in	large	cohort	studies	and	real-time	clinical	applications.	
Recently,	ultrafast	fitting	algorithms,	such	as	the	AMICO	framework,	have	been	developed	to	
address	the	computational	cost	of	model-based	microstructure-imaging	techniques.	
Through	linearization	and	convex	optimisation,	AMICO	reduces	dramatically	the	
computational	cost	of	microstructure	imaging	techniques	in	the	brain	and	locates	the	global	
minimum	parameter	values	more	reliably.	
	
	
Methods	
4	subjects	suspected	for	prostate	cancer	with	a	previous	multiparametric	prostate	MRI	
(mpMRI)	were	scanned	for	VERDICT	analysis.	For	each	subject	DW-MRI	was	performed	using	
a	3T	scanner	(Achieva,	Philips	Healthcare,	Netherlands)	using	a	pulse-gradient	spin-echo	
sequence	and	a	32	channel	cardiac	coil	with	b	values	of	90-3000s/mm	in	3	orthogonal	
directions,	5	the	imaging	parameters	are	summarised	in	Table	1.	Data	was	normalised	with	a	
b=0	image	for	every	echo	time	to	avoid	T2	dependence.	In	one	case	(subject	4),	the	scan	was	
repeated	after	a	2-minute	interval.		
MR	datasets	were	analysed	with	Osirix	Version	7.0	(Bernex,	Switzerland).	For	each	subject	a	
board	certified	radiologist	(EJ)	manually	contoured	three	regions	of	interest	(ROIs):	(1)	the	
whole	prostate,	(2)	a	region	corresponding	to	tumour	tissue	and	(3)	a	region	for	normal	
tissue	on	the	same	slice.		
The	VERDICT	model	was	fitted	to	the	data	in	each	voxel	using	both	the	original	non-linear	
fitting	algorithm	(ORIGINALVERDICT)	and	the	AMICO	framework	adapted	for	VERDICT	
(AMICOVERDICT).	ORIGINALVERDICT	uses	an	iterative	optimization	procedure2,3	that	accounts	for	
local	minima	and	Rician	noise,	as	implemented	in	the	open-source	Camino	toolkit.6	
AMICOVERDICT	expresses	the	VERDICT	model	as	a	linear	system	and	leading	to	a	convex	
optimization	problem,	which	is	solved	to	fit	the	model	to	the	data	using	freely	available	code	
(https://github.com/daducci/AMICO/).1	Both	procedures	fit	the	same	set	of	parameters.		
The	time	required	to	fit	the	models	to	the	data	is	compared.	For	subject	4	the	repeatability	
of	both	models	was	also	tested.	All	the	experiments	have	been	conducted	on	a	3.1	GHz	Intel	
Core	i7,	8	GB	ram	DDR3,	without	multi-threading	or	parallel	computing.	
Results	
Subjects’	ages	range	62.7	to	74.4	years.	In	all	cases	a	biopsy	performed	within	a	week	of	the	
scan	confirmed	cancer	with	Gleason	scores7	of	3+4.	The	computation	time	for	VERDICT	is	
reduced	with	the	AMICOVERDICT	formulation,	from	1.18s/voxel	to	0.78ms/voxel,	the	exact	
time	required	to	compute	the	parameter	maps	is	reported	in	Table	2.	
Figure	1	shows	that	AMICOVERDICT	parameter	maps	are	more	homogeneous	(less	noisy)	than	
those	obtained	with	the	original	fitting.	This	is	most	likely	because	AMICO	is	less	sensitive	to	
local	minima	–	the	more	homogeneous	minimum	objective	function	maps	(the	numerical	
values	are	not	directly	comparable)	support	this.	Both	models	show	similar	differences	in	
parameter	values	between	tumour	and	normal	tissue,	for	example,	in	both	cases	fIC	
(Intracellular	volume	fraction)	is	higher	and	fEES	(Extracellular-Extravascular	volume	
fraction)	is	lower	in	tumour	tissue	compared	with	normal	tissue.	However,	the	numerical	
values	in	Figure	2	show	differences	between	the	two	estimation	procedures,	although	both	
estimates	are	physiologically	plausible.	Both	procedures	provide	similar	reproducibility	
between	acquisitions	as	illustrated	in	Figure	3.	
Discussion	
The	principal	benefit	of	the	AMICO	framework	is	that	provides	an	acceleration	factor	of	
several	orders	of	magnitude	compared	with	non-linear	fitting,	which	we	demonstrate	here	
for	the	VERDICT	model.	AMICO	may	also	achieve	more	robust	and	repeatable	parameter	
estimates,	although	further	work	on	a	larger	cohort	and	comparison	against	histology	is	
required	to	test	this.	Improved	location	of	the	global	minimum	parameter	values	may	also	
enable	relaxation	of	some	of	the	assumptions	in	the	VERDICT	model,	such	as	fixed	
diffusivities	and	zero	permeability,	thus	supporting	more	detailed	and	accurate	
microstructural	assessment	–	future	work	will	also	evaluate	this	possibility.	
To	conclude,	AMICOVERDICT	reflect	the	microstructural	differences	between	tumours	and	
normal	tissue	in	a	clinically	practical	time.	Results	should	be	evaluated	in	larger	cohorts	to	
test	the	parameters	correlation	with	cancer	grade.	
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Figures/Tables	Captions	
• Table	1:	Diffusion	MRI	protocol	details	for	VERDICT	analysis.	
• Table	2:	Computation	time	required	by	the	original	VERDICT	and	the	AMICO-
VERDICT	for	each	analysis	in	this	study	and	the	mean	time	per	voxel.	
• Figure	1:	For	each	subject	ROIs	(red:	whole	prostate,	white:	tumour,	orange:	normal)	
and	VERDICT	maps	comparison.	fIC:	intracellular	volume	fraction,	R:	cell	radius,	
Cellularity:	calculated	dividing	the	fIC	by	the	cell	volume,	fEES:	extracellular-
extravascular	volume	fraction,	fVASC:	vascular	volume	fraction,	fobj:	objective	
function	to	evaluate	the	measures’	stability.	
• Figure	2:	ORIGINALVERDICT	and	AMICOVERDICT	parameter	estimation	for	all	voxels	within	
the	tumour	and	normal	ROIs.	Edges	of	the	boxes	define	the	25th	and	75th	percentile	
range	and	the	central	mark	is	the	median	value.	
• Figure	3:	Subject	4	parameters	estimation	comparison	between	two	different	
acquisitions.	Estimation	for	all	voxels	within	the	tumour	and	normal	ROIs	for	both	
models	(ORIGINALVERDICT	and	AMICOVERDICT).	Edges	of	the	boxes	define	the	25th	and	
75th	percentile	range	and	the	central	mark	is	the	median	value.	
	
	
	
	
	
	
Table	1:	Diffusion	MRI	protocol	details	for	VERDICT	analysis	
	
	
	
Patient	
Voxels	
1	
9544	
2	
2924	
3	
2746	
4	(Acq.	1)	
6363	
4	(Acq.	2)	
6186	 One	Voxel		
ORIGINALVERDICT	 163.52	min	 56.65	min	 59.48	min	 122.58	min	 126.91	min	 1.18	s	
AMICOVERDICT	 7	s	 3	s	 2	s	 5	s	 4	s	 0.78	ms	
	
Table	2:	Computation	time	required	by	the	original	VERDICT	and	the	AMICO-VERDICT	for	
each	analysis	in	this	study	and	the	mean	time	per	voxel.	
	
	 	
b	value	[s/mm2	]	 												∆/	δ	[ms]	 			TE	[ms]	 					|G|	[T/m]	
3000	 24.7/43.8	 90	 0.0439	
2000	 13.2/32.3	 67	 0.0758	
1500	 24.7/43.4	 90	 0.0311	
500	 12.2/31.3	 65	 0.0415	
90	 12.2/23.8	 50	 0.0506	
	
Figure	1:	For	each	subject	ROIs	(red:	whole	prostate,	white:	tumour,	orange:	normal)	and	
VERDICT	maps	comparison.	fIC:	intracellular	volume	fraction,	R:	cell	radius,	Cellularity:	
calculated	dividing	the	fIC	by	the	cell	volume,	fEES:	extracellular-extravascular	volume	
fraction,	fVASC:	vascular	volume	fraction,	fobj:	objective	function	to	evaluate	the	measures’	
stability.	
	
	
	
	
	
Figure	2:	ORIGINALVERDICT	and	AMICOVERDICT	parameter	estimation	for	all	voxels	within	the	
tumour	and	normal	ROIs.	Edges	of	the	boxes	define	the	25th	and	75th	percentile	range	and	
the	central	mark	is	the	median	value.	
	
	
Figure	3:	Subject	4	parameters	estimation	comparison	between	two	different	acquisitions.	
Estimation	for	all	voxels	within	the	tumour	and	normal	ROIs	for	both	procedures	
(ORIGINALVERDICT	and	AMICOVERDICT).	Edges	of	the	boxes	define	the	25th	and	75th	percentile	
range	and	the	central	mark	is	the	median	value.	
